These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. Wilks AB; Christian EC; Seaman MS; Sircar P; Carville A; Gomez CE; Esteban M; Pantaleo G; Barouch DH; Letvin NL; Permar SR J Immunol; 2010 Dec; 185(11):7097-106. PubMed ID: 21041730 [TBL] [Abstract][Full Text] [Related]
6. Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. Sixsmith JD; Panas MW; Lee S; Gillard GO; White K; Lifton MA; Balachandran H; Mach L; Miller JP; Lavine C; DeMarco CT; Tomaras GD; Gee C; Porcelli SA; Larsen MH; Frothingham R; Schmitz JE; Jacobs WR; Haynes BF; Letvin NL; Korioth-Schmitz B Clin Vaccine Immunol; 2014 Oct; 21(10):1385-95. PubMed ID: 25080550 [TBL] [Abstract][Full Text] [Related]
7. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575 [TBL] [Abstract][Full Text] [Related]
8. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263 [TBL] [Abstract][Full Text] [Related]
9. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. Barratt-Boyes SM; Soloff AC; Gao W; Nwanegbo E; Liu X; Rajakumar PA; Brown KN; Robbins PD; Murphey-Corb M; Day RD; Gambotto A J Gen Virol; 2006 Jan; 87(Pt 1):139-149. PubMed ID: 16361426 [TBL] [Abstract][Full Text] [Related]
10. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. Virnik K; Nesti E; Dail C; Hockenbury M; Ni Y; Felber BK; Schief WR; Berkower I Vaccine; 2017 May; 35(24):3272-3278. PubMed ID: 28483193 [TBL] [Abstract][Full Text] [Related]
11. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector. Knuchel MC; Marty RR; Morin TN; Ilter O; Zuniga A; Naim HY Hum Vaccin Immunother; 2013 Mar; 9(3):599-606. PubMed ID: 23324399 [TBL] [Abstract][Full Text] [Related]
12. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. Schell JB; Rose NF; Bahl K; Diller K; Buonocore L; Hunter M; Marx PA; Gambhira R; Tang H; Montefiori DC; Johnson WE; Rose JK J Virol; 2011 Jun; 85(12):5764-72. PubMed ID: 21490100 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931 [TBL] [Abstract][Full Text] [Related]
14. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys. Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628 [TBL] [Abstract][Full Text] [Related]
15. Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity. Korioth-Schmitz B; Perley CC; Sixsmith JD; Click EM; Lee S; Letvin NL; Frothingham R Vaccine; 2015 Oct; 33(42):5715-5722. PubMed ID: 26192357 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Van Rompay KK; Abel K; Earl P; Kozlowski PA; Easlick J; Moore J; Buonocore-Buzzelli L; Schmidt KA; Wilson RL; Simon I; Moss B; Rose N; Rose J; Marthas ML Vaccine; 2010 Feb; 28(6):1481-92. PubMed ID: 19995539 [TBL] [Abstract][Full Text] [Related]
17. A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly. Sciaranghella G; Lakhashe SK; Ayash-Rashkovsky M; Mirshahidi S; Siddappa NB; Novembre FJ; Velu V; Amara RR; Zhou C; Li S; Li Z; Frankel FR; Ruprecht RM Vaccine; 2011 Jan; 29(3):476-86. PubMed ID: 21070847 [TBL] [Abstract][Full Text] [Related]
18. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice. Andersson AC; Holst PJ J Transl Med; 2016 Dec; 14(1):343. PubMed ID: 27998269 [TBL] [Abstract][Full Text] [Related]